GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytokinetics Inc (NAS:CYTK) » Definitions » EV-to-FCF

Cytokinetics (Cytokinetics) EV-to-FCF : -16.42 (As of May. 10, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Cytokinetics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Cytokinetics's Enterprise Value is $6,827.78 Mil. Cytokinetics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-415.75 Mil. Therefore, Cytokinetics's EV-to-FCF for today is -16.42.

The historical rank and industry rank for Cytokinetics's EV-to-FCF or its related term are showing as below:

CYTK' s EV-to-FCF Range Over the Past 10 Years
Min: -681.32   Med: -6.99   Max: 72.25
Current: -16.43

During the past 13 years, the highest EV-to-FCF of Cytokinetics was 72.25. The lowest was -681.32. And the median was -6.99.

CYTK's EV-to-FCF is ranked worse than
100% of 388 companies
in the Biotechnology industry
Industry Median: 6.5 vs CYTK: -16.43

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-10), Cytokinetics's stock price is $63.00. Cytokinetics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-5.450. Therefore, Cytokinetics's PE Ratio for today is At Loss.


Cytokinetics EV-to-FCF Historical Data

The historical data trend for Cytokinetics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytokinetics EV-to-FCF Chart

Cytokinetics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.76 -545.55 -19.14 -13.87 -20.75

Cytokinetics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.87 -8.50 -7.58 -6.87 -20.75

Competitive Comparison of Cytokinetics's EV-to-FCF

For the Biotechnology subindustry, Cytokinetics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cytokinetics's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cytokinetics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Cytokinetics's EV-to-FCF falls into.



Cytokinetics EV-to-FCF Calculation

Cytokinetics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=6827.779/-415.749
=-16.42

Cytokinetics's current Enterprise Value is $6,827.78 Mil.
Cytokinetics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-415.75 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cytokinetics  (NAS:CYTK) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Cytokinetics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=63.00/-5.450
=At Loss

Cytokinetics's share price for today is $63.00.
Cytokinetics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.450.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Cytokinetics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Cytokinetics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Cytokinetics (Cytokinetics) Business Description

Traded in Other Exchanges
Address
350 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Executives
Robert I Blum officer: EVP, Corp. Development & CBO 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
John T Henderson director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Fady Ibraham Malik officer: SVP Research & Early Dev 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Wendall Wierenga director 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Muna Bhanji director C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Robert Wong officer: VP, Chief Accounting Officer 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Ching Jaw officer: SVP Finance & CFO 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Sandford D Smith director C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
B Lynne Parshall director 2855 GAZELLE COURT, CARLSBAD CA 92010
Santo J Costa director
Kaye Edward M. Md director 3450 MONTE VILLA PARKWAY, BOTHELL WA 98011
Robert Arthur Harrington director C/O CYTOKINETICS, INCORPORATED, 350 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080
Mark A Schlossberg officer: SVP - Legal & General Counsel C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544
David Cragg officer: V.P., Human Resources 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
L Patrick Gage director C/O NEOSE TECHNOLOGIES, 102 WITMER RD, HORSHAM PA 19044